Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518073 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
A Phase 2 study of Alzheimer Disease (AD), sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT03518073 is a Phase 2 study of Alzheimer Disease (AD) that has completed, run by Eli Lilly and Company. The registered enrollment target is 360 participants, above the 193-participant average among 5 other Alzheimer Disease (AD) trials with a reported enrollment target (87% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03518073, a Phase 2 study of Alzheimer Disease (AD), has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zagotenemab
Study Locations (20)
California
- Pharmacology Research Institute - Encino
- Fullerton Neurology and Headache Center - Fullerton
- Irvine Clinical Research Center - Irvine
- Pharmacology Research Institute - Los Alamitos
- National Research Institute - Huntington Park - Panorama City
- Anderson Clinical Research - Redlands
- Pacific Research Network - San Diego
- Univ of California San Francisco - San Francisco
- Syrentis Clinical Research - Santa Ana
Florida
- JEM Research Institute - Atlantis
- Julie B. Schwartzbard, MD, PA - Aventura
- Quantum Laboratories Clinical Research - Deerfield Beach
- Brain Matters Research - Delray Beach
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Infinity Clinical Research, LLC - Hollywood
- VIN-Victor Faradji - Miami
- Renstar Medical Research - Ocala
Arizona
- Banner Alzheimer's Institute - Phoenix
- Center for Neurosciences - Tucson
Connecticut
- New England Institute for Clinical Research - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518073
The ClinicalTrials.gov registry entry for NCT03518073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 193-participant average among 5 other Alzheimer Disease (AD) trials with a reported enrollment target (87% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03518073 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03518073 about?
NCT03518073 is a clinical study titled "A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
What is the current status of trial NCT03518073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2018-04-30. Estimated completion is 2021-10-25.
What conditions does trial NCT03518073 study?
This clinical trial studies the following conditions: Alzheimer Disease (AD).
What interventions are being tested in trial NCT03518073?
The interventions under investigation include: Placebo (DRUG), Zagotenemab (DRUG).
Who is sponsoring clinical trial NCT03518073?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03518073 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
RECRUITING · NA
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Brain NAD in Alzheimer's Disease
RECRUITING
-
Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)
ACTIVE NOT RECRUITING
-
Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.